Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

Science

Volumn 279, Issue 5349, 1998, Pages 377-380

  Arap, Wadih ^a   Pasqualini, Renata ^a   Ruoslahti, Erkki ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SPECIFICITY; DRUG TARGETING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BACTERIOPHAGES; CORONARY VESSELS; DOXORUBICIN; DRUG CARRIERS; HEART; HUMANS; INTEGRIN ALPHAV; INTEGRINS; LIVER; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; PEPTIDE LIBRARY; RANDOM ALLOCATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032535999     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.279.5349.377     Document Type: Article

References (43)

1. J. Folkman, Nature Med. 1, 27 (1995); W. Risau and I. Flamme, Annu. Rev. Cell Biol. 11, 73 (1995); D. Hanahan and J. Folkman, Cell 86, 353 (1996); J. Folkman, Nature Biotechnol. 15, 510 (1997).
2. J. Folkman, Nature Med. 1, 27 (1995); W. Risau and I. Flamme, Annu. Rev. Cell Biol. 11, 73 (1995); D. Hanahan and J. Folkman, Cell 86, 353 (1996); J. Folkman, Nature Biotechnol. 15, 510 (1997).
3. J. Folkman, Nature Med. 1, 27 (1995); W. Risau and I. Flamme, Annu. Rev. Cell Biol. 11, 73 (1995); D. Hanahan and J. Folkman, Cell 86, 353 (1996); J. Folkman, Nature Biotechnol. 15, 510 (1997).
4. J. Folkman, Nature Med. 1, 27 (1995); W. Risau and I. Flamme, Annu. Rev. Cell Biol. 11, 73 (1995); D. Hanahan and J. Folkman, Cell 86, 353 (1996); J. Folkman, Nature Biotechnol. 15, 510 (1997).
5. P. C. Brooks, R. A. F. Clark, D. A. Cheresh, Science 264, 569 (1994); P. C. Brooks et al., Cell 79, 1157 (1994); M. Friedlander et al., Science 270, 1500 (1995); H. P. Hammes, M. Brownlee, A. Jonczyk, A. Sutter, K. T. Preissner, Nature Med. 2, 529 (1996).
6. P. C. Brooks, R. A. F. Clark, D. A. Cheresh, Science 264, 569 (1994); P. C. Brooks et al., Cell 79, 1157 (1994); M. Friedlander et al., Science 270, 1500 (1995); H. P. Hammes, M. Brownlee, A. Jonczyk, A. Sutter, K. T. Preissner, Nature Med. 2, 529 (1996).
7. P. C. Brooks, R. A. F. Clark, D. A. Cheresh, Science 264, 569 (1994); P. C. Brooks et al., Cell 79, 1157 (1994); M. Friedlander et al., Science 270, 1500 (1995); H. P. Hammes, M. Brownlee, A. Jonczyk, A. Sutter, K. T. Preissner, Nature Med. 2, 529 (1996).
8. P. C. Brooks, R. A. F. Clark, D. A. Cheresh, Science 264, 569 (1994); P. C. Brooks et al., Cell 79, 1157 (1994); M. Friedlander et al., Science 270, 1500 (1995); H. P. Hammes, M. Brownlee, A. Jonczyk, A. Sutter, K. T. Preissner, Nature Med. 2, 529 (1996).
9. G. Martini-Baron and D. Marme, Curr. Opin. Biotechnol. 6, 675 (1995); D. Hanahan, Science 277, 48 (1997); W. Risau, Nature 386, 671 (1997).
10. G. Martini-Baron and D. Marme, Curr. Opin. Biotechnol. 6, 675 (1995); D. Hanahan, Science 277, 48 (1997); W. Risau, Nature 386, 671 (1997).
11. G. Martini-Baron and D. Marme, Curr. Opin. Biotechnol. 6, 675 (1995); D. Hanahan, Science 277, 48 (1997); W. Risau, Nature 386, 671 (1997).
12. R. Pasqualini and E. Ruoslahti, Nature 380, 364 (1996).
13. D. Rajotte et al., in preparation.
14. 5C library: CGSLVRC (35%), CGLSDSC (12%), CYTADPC (8%), CDDSWKC (8%), CPRGSRC (4%).
15. E. Ruoslahti, Annu. Rev. Cell Dev. Biol. 12, 697 (1996).
16. Abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
17. E. Koivunen, B. Wang, E. Ruoslahti, Biotechnology 13, 265 (1995).
18. R. Pasqualini, E. Koivunen, E. Ruoslahti, Nature Biotechnol. 15, 542 (1997).
19. E. Koivunen, D. Gay, E. Ruoslahti, J. Biol. Chem. 268, 20205 (1993); E. Koivunen, B. Wang, E. Ruoslahti, J. Cell Biol. 124, 373 (1994); J. M. Healy et al., Biochemistry 34, 3948 (1995).
20. E. Koivunen, D. Gay, E. Ruoslahti, J. Biol. Chem. 268, 20205 (1993); E. Koivunen, B. Wang, E. Ruoslahti, J. Cell Biol. 124, 373 (1994); J. M. Healy et al., Biochemistry 34, 3948 (1995).
21. E. Koivunen, D. Gay, E. Ruoslahti, J. Biol. Chem. 268, 20205 (1993); E. Koivunen, B. Wang, E. Ruoslahti, J. Cell Biol. 124, 373 (1994); J. M. Healy et al., Biochemistry 34, 3948 (1995).
22. W. Arap, R. Pasqualini, E. Ruoslahti, unpublished data.
23. Tumor-bearing mice (70) were anesthetized with Avertin intraperitoneally and phage or drugs were administered into the tail vein. All animal experimentation was reviewed and approved by the institute's Animal Research Committee.
24. R. K. Jain, Cancer Metastasis Rev. 9, 253 (1996); C. H. Blood and B. R. Zetter, Biochim. Biophys. Acta 1032, 89 (1990); H. F. Dvorak, J. A. Nagy, A. M. Dvorak, Cancer Cells 3, 77 (1991); T. R. Shockley et al., Ann. N.Y. Acad. Sci. 618, 367 (1991).
25. R. K. Jain, Cancer Metastasis Rev. 9, 253 (1996); C. H. Blood and B. R. Zetter, Biochim. Biophys. Acta 1032, 89 (1990); H. F. Dvorak, J. A. Nagy, A. M. Dvorak, Cancer Cells 3, 77 (1991); T. R. Shockley et al., Ann. N.Y. Acad. Sci. 618, 367 (1991).
26. R. K. Jain, Cancer Metastasis Rev. 9, 253 (1996); C. H. Blood and B. R. Zetter, Biochim. Biophys. Acta 1032, 89 (1990); H. F. Dvorak, J. A. Nagy, A. M. Dvorak, Cancer Cells 3, 77 (1991); T. R. Shockley et al., Ann. N.Y. Acad. Sci. 618, 367 (1991).
27. R. K. Jain, Cancer Metastasis Rev. 9, 253 (1996); C. H. Blood and B. R. Zetter, Biochim. Biophys. Acta 1032, 89 (1990); H. F. Dvorak, J. A. Nagy, A. M. Dvorak, Cancer Cells 3, 77 (1991); T. R. Shockley et al., Ann. N.Y. Acad. Sci. 618, 367 (1991).
28. M. S. Bretscher, EMBO J. 8, 1341 (1989); S. L. Hart et al., J. Biol. Chem. 269, 12468 (1994).
29. M. S. Bretscher, EMBO J. 8, 1341 (1989); S. L. Hart et al., J. Biol. Chem. 269, 12468 (1994).
30. A complete immunostaining panel of control organs is available online at www.burnham-inst.org/papers/ arapetal.
31. M. R. Getter, M. E. Trigg, C. R. Merril, Nature 246, 221 (1973).
32. The peptides RGD-4C (9, 10), CNGRC, CGSLVRC, and GACVFSIAHECGA were synthesized, cyclized at high dilution, and purified by high-performance liquid chromatography (HPLC). The peptides were conjugated to dox (Aldrich) with 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide hydrochloride (EDC; Sigma) and N-hydroxysuccinimide (NHS; Sigma) [S. Bauminger and M. Wilcheck, Methods Enzymol. 70, 151 (1980)]. The conjugates were freed of reactants by gel filtration on a Sephadex G25 and contained <5% free drug, as assessed by HPLC and nuclear magnetic resonance (NMR). The carbodiimide conjugation method precluded a determination of the stoichiometry of the conjugates by mass spectrometry. Preliminary experiments (72) with a compound prepared by a different chemistry [A. Nagy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 7269 (1996)] were homogeneous by HPLC, had a peptide-dox ratio of 1, and had an antitumor activity similar to that of the carbodiimide conjugates.
33. The peptides RGD-4C (9, 10), CNGRC, CGSLVRC, and GACVFSIAHECGA were synthesized, cyclized at high dilution, and purified by high-performance liquid chromatography (HPLC). The peptides were conjugated to dox (Aldrich) with 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide hydrochloride (EDC; Sigma) and N-hydroxysuccinimide (NHS; Sigma) [S. Bauminger and M. Wilcheck, Methods Enzymol. 70, 151 (1980)]. The conjugates were freed of reactants by gel filtration on a Sephadex G25 and contained <5% free drug, as assessed by HPLC and nuclear magnetic resonance (NMR). The carbodiimide conjugation method precluded a determination of the stoichiometry of the conjugates by mass spectrometry. Preliminary experiments (72) with a compound prepared by a different chemistry [A. Nagy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 7269 (1996)] were homogeneous by HPLC, had a peptide-dox ratio of 1, and had an antitumor activity similar to that of the carbodiimide conjugates.
34. R. Steiner, in Angiogenesis: Key Principles - Science, Technology and Medicine, R. Steiner, P. B. Weisz, R. Langer, Eds. (Birkhauser, Basel, Switzerland, 1992), pp. 449-454.
35. D. P. Berger, B. R. Winterhalter, H. H. Fiebig, in The Nude Mouse in Oncology Research, E. Boven and B. Winograd, Eds. (CRC Press, Boca Raton, FL, 1991), pp. 165-184.
36. The concentration of dox was adjusted by measuring the absorbance of the drug and conjugates at 490 nm. A calibration curve for dox was used to calculate the dox-equivalent concentrations. Experiments with MDA-MB-435 cells and activated endothelial cells in vitro showed that the conjugation process did not affect the cytotoxicity of dox after conjugation.
37. M. Sakamoto, R. Pasqualini, E. Ruoslahti, unpublished data.
38. R. Max et al., Int. J. Cancer 71, 320 (1997); ibid. 72, 706 (1997).
39. R. Max et al., Int. J. Cancer 71, 320 (1997); ibid. 72, 706 (1997).
40. J. Denekamp, Br. J. Radiol. 66, 181 (1993), F. J. Burrows and P. E. Thorpe, Pharmacol. Ther. 64, 155 (1994); J. Folkman, in Cancer: Principles and Practice of Oncology, V. T. DeVita, S. Hellman, S. A. Rosenberg, Eds. (Lippincott, Philadelphia, 1997), pp. 3075-3085.
41. J. Denekamp, Br. J. Radiol. 66, 181 (1993), F. J. Burrows and P. E. Thorpe, Pharmacol. Ther. 64, 155 (1994); J. Folkman, in Cancer: Principles and Practice of Oncology, V. T. DeVita, S. Hellman, S. A. Rosenberg, Eds. (Lippincott, Philadelphia, 1997), pp. 3075-3085.
42. J. Denekamp, Br. J. Radiol. 66, 181 (1993), F. J. Burrows and P. E. Thorpe, Pharmacol. Ther. 64, 155 (1994); J. Folkman, in Cancer: Principles and Practice of Oncology, V. T. DeVita, S. Hellman, S. A. Rosenberg, Eds. (Lippincott, Philadelphia, 1997), pp. 3075-3085.
43. We thank E. Beutler, W. Fenical, and T. Friedmann for comments on the manuscript; N. Assa-Munt for NMR analysis; R. Kain, S. Krajewski, and M. Sakamoto for histological analysis; W. P. Tong for HPLC analysis; G. Alton and J. Etchinson for mass spectrometry analysis; E. Koivunen for a phage library; and S. Levinton-Kriss for the SLK cell line. Supported by grants CA74238-01, CA62042, and Cancer Center support grant CA30199 from the National Cancer Institute, and by the Susan G. Komen Breast Cancer Foundation.